John A. Borgeson
Known title: See RemarksCIK: 0001754045
Associated companies
Transaction History
| KOD | ▲ Buy | Option Exercise | 30,000 | $31K | 6/4/2026 | View on chart |
| KOD | ▼ Sell | Open Market | 25,896 | $881K | 6/4/2026 | View on chart |
| KOD | ▼ Sell | Open Market | 4,104 | $142K | 6/4/2026 | View on chart |
| KOD | ▲ Buy | Option Exercise | 28,614 | $30K | 4/15/2026 | View on chart |
| KOD | ▼ Sell | Open Market | 12,477 | $503K | 4/2/2026 | View on chart |
| KOD | ▼ Sell | Open Market | 4,231 | $173K | 4/2/2026 | View on chart |
| KOD | ▼ Sell | Open Market | 600 | $25K | 4/2/2026 | View on chart |
| KOD | ▲ Buy | Option Exercise | 30,000 | $31K | 4/2/2026 | View on chart |
| KOD | ▼ Sell | Open Market | 12,692 | $497K | 4/2/2026 | View on chart |
| KOD | ▼ Sell | Open Market | 723 | $3K | 6/17/2025 | View on chart |
| KOD | ▲ Buy | Option Exercise | 1,875 | — | 6/15/2025 | View on chart |
| KOD | ▼ Sell | Open Market | 2,874 | $8K | 6/17/2024 | View on chart |
| KOD | ▲ Buy | Option Exercise | 5,494 | — | 6/15/2024 | View on chart |
| KOD | ▼ Sell | Open Market | 1,558 | $5K | 6/12/2024 | View on chart |
| KOD | ▲ Buy | Option Exercise | 3,025 | — | 6/11/2024 | View on chart |
| KOD | ▼ Sell | Open Market | 2,749 | $25K | 6/16/2023 | View on chart |
| KOD | ▲ Buy | Option Exercise | 5,494 | — | 6/15/2023 | View on chart |
| KOD | ▼ Sell | Open Market | 1,448 | $14K | 6/14/2023 | View on chart |
| KOD | ▲ Buy | Option Exercise | 3,025 | — | 6/11/2023 | View on chart |
| KOD | ▼ Sell | Open Market | 2,798 | $20K | 6/17/2022 | View on chart |
| KOD | ▲ Buy | Option Exercise | 5,494 | — | 6/15/2022 | View on chart |
| KOD | ▼ Sell | Open Market | 1,545 | $11K | 6/15/2022 | View on chart |
| KOD | ▲ Buy | Option Exercise | 3,025 | — | 6/11/2022 | View on chart |
| KOD | ▼ Sell | Open Market | 672 | $77K | 11/10/2021 | View on chart |
| KOD | ▼ Sell | Open Market | 204 | $24K | 11/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Kodiak Sciences (KOD) Analyst Raises Target, Presents Late‑Stage Data
HC Wainwright & Co. kept its positive stance on Kodiak Sciences and lifted its price target to $126. The company will share clinical results from three late‑stage programs at the American Academy of Ophthalmology conference. Recent reports note the stock is trading at a premium after trial news, while some analysts consider it potentially overvalued. It also appears on a list of health‑care stocks that could face difficulties in Q4.
Kodiak Sciences (KOD) Analyst Raises Target, Presents Late‑Stage Data. HC Wainwright & Co. kept its positive stance on Kodiak Sciences and lifted its price target to $126. The company will share clinical results from three late‑stage programs at the American Academy of Ophthalmology conference. Recent reports note the stock is trading at a premium after trial news, while some analysts consider it potentially overvalued. It also appears on a list of health‑care stocks that could face difficulties in Q4.